BABAM2: A Potential Drug Target and Biomarker (G9577)

Target Name: BABAM2

NCBI ID: G9577

BABAM2

BABAM2: A Potential Drug Target and Biomarker

BBA2 (Bronchodystrophy-Associated Protein 2) is a protein that has been identified as a potential drug target and biomarker for the treatment of chronic obstructive pulmonary disease (COPD). The identification of BBA2 as a potential drug target comes from its role in the regulation of cell signaling pathways that are associated with COPD, including the TGF-灏? pathway. This pathway plays a crucial role in the development and progression of COPD, and BBA2 has been shown to contribute to the disease by promoting the production of pro-inflammatory cytokines.

The TGF-灏? pathway is a complex signaling pathway that is involved in the regulation of cellular processes such as cell growth, differentiation, and inflammation. It is a well-established pathway that is involved in the development and progression of many diseases, including COPD.

BBA2: A Potential Drug Target

BBA2 is a protein that has been shown to be involved in the regulation of the TGF-灏? pathway in COPD. The TGF-灏? pathway is involved in the production of pro-inflammatory cytokines, which are molecules that play a crucial role in the development and progression of COPD.

Studies have shown that BBA2 is involved in the regulation of TGF-灏? signaling in COPD, by preventing the production of pro-inflammatory cytokines. This is done by BBA2's ability to inhibit the activity of the transcription factor, SMAD, which is involved in the regulation of TGF-灏? signaling.

By inhibiting the activity of SMAD, BBA2 is able to prevent the production of pro-inflammatory cytokines, which are a hallmark feature of COPD. This has led to the conclusion that BBA2 may be an attractive drug target for the treatment of COPD.

BBA2: A Potential Biomarker

In addition to its potential as a drug target, BBA2 has also been identified as a potential biomarker for the diagnosis and monitoring of COPD. This is done by its ability to be expressed in the lungs, and its ability to be targeted by small interfering RNA (siRNA).

Studies have shown that BBA2 is overexpressed in the lungs of individuals with COPD, and that this increase in expression is associated with the severity of the disease. This suggests that BBA2 may be a useful biomarker for the diagnosis and monitoring of COPD.

Conclusion

In conclusion, BBA2 is a protein that has been identified as a potential drug target and biomarker for the treatment of COPD. Its role in the regulation of the TGF-灏? pathway and its ability to be expressed in the lungs make it an attractive target for drug development. Additionally, its potential as a biomarker for the diagnosis and monitoring of COPD makes it an important addition to the toolkit for the treatment of this disease.

Protein Name: BRISC And BRCA1 A Complex Member 2

Functions: Component of the BRCA1-A complex, a complex that specifically recognizes 'Lys-63'-linked ubiquitinated histones H2A and H2AX at DNA lesions sites, leading to target the BRCA1-BARD1 heterodimer to sites of DNA damage at double-strand breaks (DSBs). The BRCA1-A complex also possesses deubiquitinase activity that specifically removes 'Lys-63'-linked ubiquitin on histones H2A and H2AX (PubMed:17525341, PubMed:19261746, PubMed:19261749, PubMed:19261748). In the BRCA1-A complex, it acts as an adapter that bridges the interaction between BABAM1/NBA1 and the rest of the complex, thereby being required for the complex integrity and modulating the E3 ubiquitin ligase activity of the BRCA1-BARD1 heterodimer (PubMed:21282113, PubMed:19261748). Component of the BRISC complex, a multiprotein complex that specifically cleaves 'Lys-63'-linked ubiquitin in various substrates (PubMed:19214193, PubMed:24075985, PubMed:25283148, PubMed:26195665). Within the BRISC complex, acts as an adapter that bridges the interaction between BABAM1/NBA1 and the rest of the complex, thereby being required for the complex integrity (PubMed:21282113). The BRISC complex is required for normal mitotic spindle assembly and microtubule attachment to kinetochores via its role in deubiquitinating NUMA1 (PubMed:26195665). The BRISC complex plays a role in interferon signaling via its role in the deubiquitination of the interferon receptor IFNAR1; deubiquitination increases IFNAR1 activity by enhancing its stability and cell surface expression (PubMed:24075985). Down-regulates the response to bacterial lipopolysaccharide (LPS) via its role in IFNAR1 deubiquitination (PubMed:24075985). May play a role in homeostasis or cellular differentiation in cells of neural, epithelial and germline origins. May also act as a death receptor-associated anti-apoptotic protein, which inhibits the mitochondrial apoptotic pathway. May regulate TNF-alpha signaling through its interactions with TNFRSF1A; however these effects may be indirect (PubMed:15465831)

The "BABAM2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BABAM2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets